A healthcare-focused Growth Equity firm currently manages $1 billion and provides $20-100 million of equity capital per company over the life of the investment. With offices in the US and UK, the firm is primarily looking for companies throughout North America and Europe.

The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications.

The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based multi-family office invests across several sectors, with a focus on life science and healthcare. The firm typically seek opportunities in Seed to Series A rounds, with an initial check size ranging from $500K to $3M USD. Within life science and healthcare, approximately half the firm’s investments have been in companies related to oncology, which is an area of special interest to the firm. While most of their investments have been in the US, the firm will consider opportunities in other countries like Canada and Europe. The firm is typically a co-investor.

Within life science and healthcare, the firm is interested in biotech therapeutics, medtech, and is open to diagnostics and life science tools as well. The firm is agnostic to subsectors, although cell and gene therapy is one area of interest. The firm is open to considering companies at an early stage of development, from pre-clinical to phase I for therapeutics and from in-development to clinical stage for medical devices. The firm is open to devices across all classes. For indications, oncology stands out as a particular area of interest for the firm.

While the firm does not have special requirements regarding the founding or management team. The firm does place emphasis on partnering with experienced founders and value the expertise and track record of the founder.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm newly founded in 2023 and dually headquartered in the U.S. and Europe  is looking to invest from its new fund in life science startups typically in the Series A round. Typical check size is flexible but ranges from $250k-2M. The firm is looking to invest in companies from the U.S., Europe, Israel, and the Middle East. The firm’s co-founder is NIH trained and has done consulting with the FDA, bringing their expertise to investments and companies.

The firm is investing in life science sectors including: 50% in therapeutics, 20% in medical devices, 20% in diagnostics, and 10% in health-tech. The firm is open to all modalities and technologies. In terms of therapeutics, the firm prefers companies that are Pre-Clinical up to Phase II and will not look farther than that. The firm is indication-agnostic and is open to looking at orphan diseases.

The firm may take a board seat on a case-by-case basis but does not have specific management team requirements. The firm can participate as a lead investor or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

One of the leading fully integrated biopharmaceutical companies in China with multiple integrated R&D centers in US and China is actively seeking licensing/collaboration on development candidates with first-in-class or best-in-class potentials and commercial products with substantial market opportunities in China and worldwide.

The firm is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease.

The firm is looking for companies with capacity and experience to implement R&D plans. The firm is interested in incubating companies from scratch.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund based in the US looks to make initial equity investments ranging anywhere from $750,000 and up, with most investments falling in the $2-3M million range for the life of the investment. The firm is actively seeking new investments in the US.

The firm is interested in healthcare software companies and tech-enabled healthcare services, with a deep interest in software platforms for clinical trials and pharma services. The firm is interested in B2B SaaS business models and those that have some initial customer traction. The firm is not interested in therapeutics, medical devices, or diagnostics.

The firm does not look to take controlling investments in companies. They take a board seat following investment. The firm is interested in privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in Taipei, Taiwan invests in several sectors including biotechnology, semiconductors, commerce, materials, and software. The firm will invest in companies in Series A and B in Taiwan, Japan, and the U.S. Typical check size ranges from $1-3M USD for early-stage deals. The firm also has an angel fund for Seed stage companies with typical check sizes ranging from $100-3000k USD. Currently, 70% of the firm’s portfolio companies are in Taiwan or Taiwanese-related and 30% are in the U.S. or Japan. The firm has an extended network in the U.S., especially from the Silicon Valley and Boston as most of the founding partners are from Stanford University. If the firm is investing in a Taiwanese company, they tend to lead investments, but for overseas investments, the firm will mostly act as a co-investor.

The firm focuses on biomaterials, medical devices and digital health at in-development or clinical stages. The firm does not invest in pharma or drug development. In terms of medical devices, the firm likes to look at surgery-related devices and for digital health, the firm like to look at software for long-term care. Though, firm is open to all indications and can look at orphan diseases depending on the technology.

The firm focuses on companies that can finalize assets by maximum of 9 years due to the limited fund. The firm may take an observer seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multi-family venture fund is an active investor in the medical device sector, and is interested in opportunities in the western United States. Initial investments are typically about $150,000 with the potential for follow-on investments totaling $1 million and may be structured as equity or as debt. The firm offers support and expertise to portfolio companies but does not seek a board seat.

The firm is interested in medical technology and lab equipment, including electro-mechanical medical devices, active implantable devices, and surgical instruments. The firm invests only in companies that have already developed a prototype of their product, filed a patent application and have animal data.

The firm seeks to invest in strong management teams with prior experience in the medical device industry. The firm prefers to make investments with the potential to exit within 3-4 years.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.